Component
NF-kappa-B p65 nuclear translocation in RAW 264.7 macrophages
Lipopolysaccharide-driven p65 movement into the nucleus.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Avermectin inhibited NF-kappa-B p65 translocation into the nucleus and inhibited JNK and p38 phosphorylation in lipopolysaccharide-stimulated mouse macrophages.
Experimental context and source evidence
- duration
- 30 minutes after lipopolysaccharide
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- Mouse RAW 264.7 macrophages
- exposure
- Avermectin 0.625, 1.25 or 5 mg/L for one hour before 1 mg/L lipopolysaccharide
- limitations
- The compound tested was avermectin, the parent macrocyclic lactone, not ivermectin, and tumour necrosis factor alpha, interleukin-1 beta and interleukin-10 were regulated while interleukin-6 was not significantly affected.
- organism
- Mouse RAW 264.7 macrophages
- plain_language
- Avermectin inhibited NF-kappa-B p65 translocation into the nucleus and inhibited JNK and p38 phosphorylation in lipopolysaccharide-stimulated mouse macrophages.
- primary_references
- Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. (2009). https://pubmed.ncbi.nlm.nih.gov/19453757/ DOI: 10.1111/j.1472-8206.2009.00684.x
- route
- In vitro
- tissue
- NF-kappa-B and MAP kinase signalling, cytokine output
Ivermectin: mechanism of action across parasite, host barrier and mammalian targets (2026-09-22) · lines 222–231
Original AI-assisted curation of sixteen primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Study-specific citations, concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## avermectin-nfkb-mapk-inflammation Avermectin inhibited NF-kappa-B p65 translocation into the nucleus and inhibited JNK and p38 phosphorylation in lipopolysaccharide-stimulated mouse macrophages. Model/species: Mouse RAW 264.7 macrophages Tissue/system: NF-kappa-B and MAP kinase signalling, cytokine output Exposure: Avermectin 0.625, 1.25 or 5 mg/L for one hour before 1 mg/L lipopolysaccharide Route: In vitro Duration: 30 minutes after lipopolysaccharide Limits: The compound tested was avermectin, the parent macrocyclic lactone, not ivermectin, and tumour necrosis factor alpha, interleukin-1 beta and interleukin-10 were regulated while interleukin-6 was not significantly affected. Primary reference: Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. (2009). https://pubmed.ncbi.nlm.nih.gov/19453757/ DOI: 10.1111/j.1472-8206.2009.00684.x Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.